Patients with rare diseases are increasingly working to find and fund their own cures. But should they have to?

The RABBIT registry is supported by a joint, unconditional grant from AbbVie, Alfasigma, Amgen, Biocon, Bristol Myers Squibb, ...

From drug trials to mechanistic insights, EULAR 2025 delivers wide-ranging data that may inform tomorrow’s standards in ...

AstraZeneca (NASDAQ: AZN) and Pfizer (NYSE: PFE) -- along with one biotech stock, Exelixis (NASDAQ: EXEL). (AstraZeneca): ...

On June 26, Pfizer announced positive topline results from its Phase 3 BASIS study evaluating HYMPAVZI (marstacimab) for ...

The Subject Expert Committee (SEC) functional under the Central Drugs Standard Control Organisation (CDSCO) has granted ...

The FDA has updated labels on the top two COVID-19 vaccines to warn of a rare heart side effect, mostly seen in young men.

We’ve uncovered a list of what we consider to be five recession-proof dividend stocks yielding over 6%, much higher than the ...

The FDA has expanded existing warnings on the two leading COVID-19 vaccines about a rare heart side effect mainly seen in young men.

Lantheus Holdings Inc. (NASDAQ:LNTH) is one of the most undervalued US stocks according to analysts. On June 20, Lantheus ...

June brought major prostate cancer updates, and CURE is sharing the latest FDA approvals, label expansions, and emerging data ...

Indian pharma speeds up access to global therapies while targeting treatment gaps: Nandita Vijayasimha, Bengaluru Saturday, June 28, 2025, 08:00 Hrs [IST] Indian pharma is now agg ...